doi.org/10.1038/leu.2015.274, hdl.handle.net/1765/89063
Leukemia
Department of Hematology

Cavo, M, Pantani, L, Pezzi, A, Petrucci, M, Patriarca, F, Di Raimondo, F, … Sonneveld, P. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia, 29(12), 2429–2431. doi:10.1038/leu.2015.274